Assessment of various continual reassessment method models for doseescalation phase 1 oncology clinical trials: Using real clinical data and simulation studies

The continual reassessment method (CRM) identifies the maximum tolerated dose (MTD) more efficiently and identifies the true MTD more frequently compared to standard methods such as the 3 + 3 method. An initial estimate of the dose-toxicity relationship (prior skeleton) is required, and there is limited guidance on how to select this.